Type III Dysbetalipoproteinemia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00214604|
Recruitment Status : Completed
First Posted : September 22, 2005
Last Update Posted : November 19, 2010
|Condition or disease||Intervention/treatment||Phase|
|Hyperlipoproteinemia Type III||Drug: Rosuvastatin Drug: rosuvastatin Drug: pravastatin||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||30 participants|
|Intervention Model:||Crossover Assignment|
|Official Title:||An 18-week, Randomized, Multicenter, Phase 3b, Double-blind, Crossover Study, Followed by an 18-week Open-Label Period to Evaluate the Efficacy & Safety of the Lipid-Regulating Agents, Rosuvastatin & Pravastatin in the Treatment of Subjects With Dysbetalipoproteinemia (Frederickson Type III Hyperlipoproteinemia)|
|Study Start Date :||February 2005|
|Actual Primary Completion Date :||February 2007|
|Actual Study Completion Date :||February 2007|
- Percent change from baseline in non-HDL-C after 6 weeks of treatment at a given dose during the 18-week randomized crossover period.
- Efficacy of once daily treatment with rosuvastatin 10mg, rosuvastatin 20mg and provastatin 40mg in subjects with dysbetalipoproteinemia after 6 weeks of treatment at any given dose during the 18-week randomized crossover period.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00214604
|Cape Town, South Africa|
|Study Director:||AstraZeneca Crestor Medical Sciences Director, MD||AstraZeneca|